FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns a pharmaceutical composition for reducing glucose levels, including at least one FGF-21 compound and at least one GLP-1R agonist. Group of inventions also relates to use of said pharmaceutical composition for preparing a drug for treating metabolic syndrome, diabetes, obesity or excessive weight in a patient.
EFFECT: Group of inventions provides synergetic effect in reduction of plasma glucose level.
19 cl, 2 ex, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING METABOLIC SYNDROME | 2011 |
|
RU2732703C2 |
| CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY | 2010 |
|
RU2573896C2 |
| FGF21 Fc FUNCTION PROTEIN, GLP-1 Fc FUNCTION PROTEIN AND COMBINED THERAPEUTIC AGENT INCLUDING THEM AND THEIR USE | 2020 |
|
RU2804335C2 |
| COMPOSITIONS, APPLICATIONS AND METHODS OF TREATING METABOLIC DISORDERS AND DISEASES | 2012 |
|
RU2697762C2 |
| NOVEL PROTEIN CONJUGATE AND USE THEREOF FOR PREVENTING OR TREATING NON-ALCOHOLIC STEATOHEPATITIS, OBESITY AND DIABETES | 2021 |
|
RU2822001C1 |
| OXYINTOMODULINE | 2009 |
|
RU2542362C2 |
| COMPOSITIONS AND METHODS OF USING FOR TREATING METABOLIC DISORDERS | 2014 |
|
RU2704285C2 |
| ANTIBODY SPECIFICALLY BINDING TO GLP-1R AND FUSION PROTEIN THEREOF WITH GLP-1 | 2014 |
|
RU2681857C2 |
| CANCER MODELS AND CORRESPONDING METHODS | 2014 |
|
RU2707531C2 |
| GLUCAGON/GLP-1 AGONISTS FOR THE TREATMENT OF OBESITY | 2013 |
|
RU2671088C2 |
